New York State Common Retirement Fund Sells 39,010 Shares of 10x Genomics, Inc. (NASDAQ:TXG)

New York State Common Retirement Fund trimmed its stake in 10x Genomics, Inc. (NASDAQ:TXG) by 7.6% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 476,338 shares of the company’s stock after selling 39,010 shares during the period. New York State Common Retirement Fund’s holdings in 10x Genomics were worth $6,840,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Capital Performance Advisors LLP purchased a new position in 10x Genomics in the third quarter valued at about $35,000. Blue Trust Inc. raised its stake in shares of 10x Genomics by 136.5% during the 3rd quarter. Blue Trust Inc. now owns 1,776 shares of the company’s stock worth $40,000 after acquiring an additional 1,025 shares in the last quarter. Sound Income Strategies LLC raised its stake in shares of 10x Genomics by 65.2% during the 4th quarter. Sound Income Strategies LLC now owns 3,370 shares of the company’s stock worth $48,000 after acquiring an additional 1,330 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new stake in 10x Genomics during the fourth quarter valued at approximately $52,000. Finally, Venturi Wealth Management LLC boosted its stake in 10x Genomics by 1,108.9% in the third quarter. Venturi Wealth Management LLC now owns 2,442 shares of the company’s stock valued at $55,000 after acquiring an additional 2,240 shares in the last quarter. 84.68% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, CEO Serge Saxonov sold 5,092 shares of the company’s stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $11.07, for a total value of $56,368.44. Following the completion of the transaction, the chief executive officer now owns 879,482 shares of the company’s stock, valued at approximately $9,735,865.74. This represents a 0.58 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Alan Mateo acquired 40,000 shares of the company’s stock in a transaction on Friday, February 21st. The stock was acquired at an average cost of $11.14 per share, for a total transaction of $445,600.00. Following the completion of the acquisition, the director now owns 61,691 shares of the company’s stock, valued at $687,237.74. This trade represents a 184.41 % increase in their position. The disclosure for this purchase can be found here. Insiders own 10.03% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on TXG shares. JPMorgan Chase & Co. reduced their price target on 10x Genomics from $14.00 to $12.00 and set a “neutral” rating on the stock in a research report on Thursday, February 13th. Morgan Stanley reduced their target price on 10x Genomics from $28.00 to $26.00 and set an “overweight” rating on the stock in a research report on Friday, February 14th. Weiss Ratings reissued a “sell (e+)” rating on shares of 10x Genomics in a report on Wednesday, February 19th. Leerink Partnrs downgraded shares of 10x Genomics from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 13th. Finally, Stifel Nicolaus lowered their target price on shares of 10x Genomics from $21.00 to $18.00 and set a “buy” rating for the company in a research note on Thursday, February 13th. One analyst has rated the stock with a sell rating, nine have given a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, 10x Genomics has a consensus rating of “Hold” and a consensus price target of $20.57.

10x Genomics Price Performance

Shares of 10x Genomics stock opened at $11.65 on Thursday. 10x Genomics, Inc. has a 1 year low of $10.63 and a 1 year high of $48.42. The stock has a market cap of $1.42 billion, a PE ratio of -7.66 and a beta of 1.85. The firm has a fifty day moving average price of $14.13 and a 200 day moving average price of $16.92.

10x Genomics (NASDAQ:TXG) last issued its earnings results on Wednesday, February 12th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.08). 10x Genomics had a negative return on equity of 25.40% and a negative net margin of 29.90%. As a group, equities analysts expect that 10x Genomics, Inc. will post -1.43 EPS for the current year.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.